Reduction of the Glycemic Index by a Novel Viscous Polysaccharide

July 8, 2009 updated by: Glycemic Index Laboratories, Inc

Effect of Adding the Novel Fiber, PGX®,to Commonly Consumed Foods on Glycemic Response and Glycemic Index: A Practical and Effective Strategy for Reducing Post Prandial Blood Glucose Levels.

Reductions of postprandial glucose levels have been demonstrated previously with the addition of a novel viscous polysaccharide (NVP) to a glucose drink and standard white bread. This study explores whether these reductions are sustained when NVP is added to a range of commonly consumed foods.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Recently, a commercial novel viscous polysaccharide (NVP)complex has been developed which is marketed in both the USA and Canada under the trade name PGX® (PolyGlycopleX) (InovoBiologic Inc, Calgary, AB, Canada). This complex consists of three viscous non starch polysaccharides which are processed using proprietary technology (EnviroSimplex®) to produce compressed granules which delays the onset of viscosity and increases palatability of the fiber when added to food. Previously, this fibre was shown to lower postprandial glucose levels in a dose responsive manner when mixed with a glucose drink and sprinkled onto a standard white bread demonstrating that the processing did not interfere with the effectiveness of the fiber. From this study the reduction in GI was calculated to be 7 units per gram of NVP when added to a solid food, however it is not known whether this relationship would be maintained when the NVP was added to a range of commonly eaten foods. This study therefore evaluates the effect of the addition or incorporation of NVP into a range of foods on postprandial glycemia and whether the reductions in glycemic index could be predicted using.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada
        • Glycemic Index Laboratories, Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • healthy individuals
  • 18-75 years old
  • BMI less than 35 kg/m2

Exclusion Criteria:

  • Medications influencing gastrointestinal function
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: 1
Control White bread containing 50g available carbohydrate
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 2
White bread and milk control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 3
Granola control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 4
Cornflakes and milk control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 5
White rice control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 6
Fruit yogurt control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 7
Turkey dinner control
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 8
Granola
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 9
Cornflakes and milk
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 10
White Rice
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 11
Fruit yogurt
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 12
Turkey dinner
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 13
White Bread
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Placebo Comparator: 14
White bread
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX
Experimental: 15
Granola
Dietary supplement: PolyGlycopleX (PGX)
2.5 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
5.0 grams of PGX
Dietary supplement: PolyGlycopleX (PGX)
0 grams of PGX

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Relative Blood glucose response of food with and without NVP
Time Frame: Acute blood glucose response measured at 0, 15,30,45,60,90 and 120 min
Acute blood glucose response measured at 0, 15,30,45,60,90 and 120 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Glycemic Index Laboratories, Inc

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Canadian Center for Functional Medicine
InovoBiologic Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2006

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2006

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2006

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 25, 2009

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2009

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 9, 2009

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 9, 2009

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2009

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2009

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GIL-6033

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Glucose, Postprandial

Clinical Trials on PolyGlycopleX (PGX)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings